Lon­nie Moul­der's Zenas clos­es a $200M Se­ries C to broad­en lead drug's au­toim­mune po­ten­tial

Lon­nie Moul­der’s lat­est biotech has se­cured some new cash to ex­pand its work in au­toim­mune dis­eases.

The start­up, Zenas Bio­Phar­ma, closed a $200 mil­lion Se­ries C and will use the mon­ey to fund clin­i­cal tri­als for its lead pro­gram, obex­e­limab. Zenas is test­ing the drug in Phase 3 for IgG4-re­lat­ed dis­ease — which can cause tu­mor-like growths on some or­gans — and in Phase 2 for mul­ti­ple scle­ro­sis, sys­temic lu­pus ery­the­mato­sus and warm au­toim­mune he­molyt­ic ane­mia.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER